Premature Ovarian Failure Clinical Trials

Find Premature Ovarian Failure Clinical Trials Near You

Phase Ⅰ/Ⅱa Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Injection of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in Patients With Premature Ovarian Insufficiency (POI)

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

A Phase I/IIa clinical study evaluating the safety, tolerability and efficacy of intravenously administered human umbilical cord mesenchymal stem cell (hUC-MSCs) injection in patients with premature ovarian insufficiency (POI). The primary objective of the Phase I dose-escalation stage is to assess the safety and tolerability of intravenous infusion of hUC-MSCs injection for the treatment of POI, and to determine the recommended phase II dose (RP2D) for the Phase IIa clinical trial. The primary objective of the Phase IIa dose-expansion stage is to evaluate the efficacy of intravenous infusion of hUC-MSCs injection in POI treatment, and to generate data to support pivotal/confirmatory clinical trials.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 40
Healthy Volunteers: f
View:

• Aged 18 to 40 years at the time of signing the informed consent form (exclusive of the boundary values);

• Meet the diagnostic criteria specified in the Expert Consensus on Clinical Diagnosis and Treatment of Premature Ovarian Insufficiency (2023 Edition): oligomenorrhea (menstrual cycle longer than 35 days) or amenorrhea for more than 4 months, with basal serum follicle-stimulating hormone (FSH) \> 25 U/L (tested on Days 2-4 of the menstrual cycle or during amenorrhea, at least twice with an interval of ≥4 weeks);

• Satisfy one of the following two criteria:

‣ Total number of antral follicles (AFC) with a diameter of 2-10 mm in bilateral ovaries \< 5;

⁃ Serum anti-Müllerian hormone (AMH) ≤ 7.85 pmol/L (equivalent to 1.1 ng/mL);

• Have received standardized hormone replacement therapy (HRT) at a stable dose for ≥3 months prior to drug administration with stable hormone levels, and maintain stable HRT per medical advice throughout the trial (within 24 weeks after enrollment);

• Have no fertility requirements;

• Agree to use effective contraceptive measures throughout the trial period (such as complete abstinence, condoms, cervical caps plus spermicides, intrauterine devices, etc.);

• Negative serum β-hCG test result during the screening period (to rule out pregnancy);

• Fully understand the trial information and sign the informed consent form.

Locations
Other Locations
China
Peking Union Medical College Hospital
RECRUITING
Beijing
Contact Information
Primary
Xiaohong Wang,MD
xiaohong@wingor.net
+86 755 6683 5786
Time Frame
Start Date: 2026-08-03
Estimated Completion Date: 2029-08-02
Participants
Target number of participants: 59
Treatments
Experimental: Phase I, Dose Cohort 1
Human Umbilical Cord Mesenchymal Stem Cells Injection
Experimental: Phase I, Dose Cohort 2
Human Umbilical Cord Mesenchymal Stem Cells Injection
Experimental: Phase I, Dose Cohort 3
Human Umbilical Cord Mesenchymal Stem Cells Injection
Experimental: Phase IIa, Medium-Dose Cohort
Human Umbilical Cord Mesenchymal Stem Cells Injection
Experimental: Phase IIa, High-Dose Cohort
Human Umbilical Cord Mesenchymal Stem Cells Injection
Placebo_comparator: Phase IIa, Placebo Cohort
Multiple Electrolytes Injection
Related Therapeutic Areas
Sponsors
Leads: Shenzhen Wingor Biotechnology Co., Ltd.

This content was sourced from clinicaltrials.gov